Skip to main content

Table 1 Clinical and virological characteristics of patients

From: Analysis of HCV quasispecies dynamic under selective pressure of combined therapy

Patient and type of treatment responsea

Sex

Age

HCV Genotype

Sample

Viral Load log UI/ml

Genetic Distance

Genetic Distance from baselineb

Shannon Entropy

SVR

        

P05

F

44

1b

6.04

0.006 ± 0.001

 

0.0096

P35

M

40

1a

6.25

0.005 ± 0.001

 

0.0074

P40

M

35

1a

6.57

0.004 ± 0.001

 

0.0042

NR

        

P08

F

41

1a

5.80

0.008 ± 0.001

 

0.0126

    

12wt

4.59

0.009 ± 0.001

0.009 ± 0.001

0.0113

    

14d

6.18

0.011 ± 0.001

0.014 ± 0.002

0.0157

    

2m

6.46

0.008 ± 0.001

0.014 ± 0.002

0.0103

    

6m

6.40

0.007 ± 0.001

0.015 ± 0.002

0.0156

P11

M

72

1b

6.85

0.017 ± 0.001

 

0.0235

    

12wt

3.71

0.007 ± 0.001

0.020 ± 0.003

0.0140

    

14d

6.27

0.005 ± 0.001

0.032 ± 0.004

0.0134

    

2m

6.73

0.007 ± 0.001

0.034 ± 0.004

0.0132

    

6m

>7.2

0.012 ± 0.002

0.030 ± 0.004

0.0192

P146

M

21

1a

6.92

0.012 ± 0.002

 

0.0202

    

12wt

5.54

0.006 ± 0.001

0.014 ± 0.002

0.0097

    

14d

6.43

0.012 ± 0.001

0.020 ± 0.002

0.0172

    

2m

6.76

0.012 ± 0.001

0.020 ± 0.002

0.0177

    

6m

6.96

0.008 ± 0.001

0.017 ± 0.002

0.0119

P44

M

51

1b

6.50

0.016 ± 0.002

 

0.0139

    

12wt

6.13

0.019 ± 0.002

0.019 ± 0.002

0.0311

    

14d

6.24

0.014 ± 0.001

0.023 ± 0.003

0.0206

    

2m

7.18

0.014 ± 0.001

0.023 ± 0.003

0.0216

    

6m

6.83

0.014 ± 0.001

0.024 ± 0.003

0.0216

ETR

        

P03

M

39

1a

5.95

0.011 ± 0.001

 

0.0131

    

28d

4.99

0.004 ± 0.001

0.041 ± 0.005

0.0094

    

2m

5.39

0.003 ± 0.001

0.039 ± 0.005

0.0058

    

3m

4.74

0.003 ± 0.001

0.039 ± 0.005

0.0055

    

4m

5.03

0.002 ± 0.001

0.039 ± 0.005

0.0073

    

5m

5.26

0.001 ± 0.001

0.038 ± 0.005

0.0033

    

6m

5.08

0.012 ± 0.000

0.038 ± 0.005

0.0038

P37

M

27

1a

6.00

0.005 ± 0.001

 

0.0137

    

2m

6.63

0.001 ± 0.001

0.017 ± 0.003

0.0055

    

3m

6.83

0.002 ± 0.001

0.016 ± 0.003

0.0038

    

4m

6.30

0.003 ± 0.001

0.016 ± 0.003

0.0066

    

5m

6.10

0.009 ± 0.001

0.017 ± 0.003

0.0074

    

6m

6.58

0.014 ± 0.001

0.019 ± 0.003

0.0109

P42

M

56

1b

6.66

0.016 ± 0.002

 

0.0161

    

4m

6.24

0.014 ± 0.002

0.030 ± 0.003

0.0162

    

5m

6.28

0.017 ± 0.002

0.028 ± 0.003

0.0141

    

6m

6.34

0.022 ± 0.002

0.030 ± 0.003

0.0145

P47

M

47

1a

6.05

0.033 ± 0.002

 

0.0268

    

2m

5.67

0.027 ± 0.003

0.039 ± 0.004

0.0466

    

3m

5.92

0.003 ± 0.002

0.039 ± 0.004

0.0391

    

4m

5.57

0.011 ± 0.001

0.037 ± 0.004

0.0072

    

5m

5.87

0.009 ± 0.002

0.038 ± 0.004

0.0197

    

6m

2.93

0.011 ± 0.002

0.041 ± 0.004

0.0171

  1. aSVR, sustained virological response; NR, non-response; ETR, end-of-treatment response.
  2. =before treatment; wt=weeks of treatment; d=days after the end of treatment; m=months after the end of treatment.